Our colleagues Günter Fingerle-Rowson, CMO, Mary Ann Lumiqued, VP Program Management, and Inês Vasconcelos, Medical Director, are looking forward to attending the upcoming ESMO - European Society for Medical Oncology’s 2024 conference, starting on September 13 in Barcelona. If you happen to be there as well, reach out and check in with them to learn more about our unique approach to #ADCs, aiming to unlock their full therapeutic potential for the treatment of #SolidTumors. The team would be happy to discuss with you the currently running clinical study for our lead candidate TUB-040 targeting NaPi2b and our clinical plan for TUB-030 targeting 5T4. To schedule a meeting on-site, simply send a direct message to Mary Ann here on LinkedIn. For further information on our pipeline, proprietary technologies and news around the company, visit www.tubulis.com. #ESMO24
Info
Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
- Website
-
http://www.tubulis.com
Externer Link zu Tubulis GmbH
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Munich, Bayern
- Art
- Privatunternehmen
- Spezialgebiete
- Antibody Drug Conjugates, Targeted Therapy, Biotechnology und Drug Development
Orte
-
Primär
Munich, Bayern 81377, DE
Beschäftigte von Tubulis GmbH
Updates
-
Are you attending the upcoming Hanson Wade Group’s #ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit from September 9-10 in Boston? Don’t miss the two talks by our CBO, Ingo Lehrke: On September 9 at 4:20 pm, he will give a presentation on how Tubulis aims to expand the therapeutic potential of #ADCs with our set of proprietary platform technologies, including an update on our clinical development programs and our next steps in seeking new conjugates for our differentiated #SolidTumor pipeline. On September 10 at 8:15 am, Ingo will participate in a panel discussion on the relevance and potential of antibody-drug conjugation in the context of protein degradation. Find the full agenda details here https://lnkd.in/eiR26qHk and check out where to meet us next at https://lnkd.in/dHstmPm
-
Meet our team at Morgan Stanley’s 22nd Annual Global #Healthcare Conference from September 4-6 in #NYC! Our CEO, Dominik Schumacher, our CBO, Ingo Lehrke, and our VP Finance, Andreas Montag, will be on-site to catch up with the financial and #biotech community and look forward to discussing any questions around our suite of proprietary platform technologies, our pipeline of uniquely matched #ADCs for #SolidTumors or the next steps on our clinical development path. Send a direct message to Ingo here on LinkedIn to schedule a meeting. In the meantime, check out our website www.tubulis.com for further information on our science, candidates and upcoming events.
-
Tubulis is expanding! We are excited to announce the establishment of our US subsidiary, Tubulis Inc., located at the renown CIC (Cambridge Innovation Center) right in the heart of the vibrant Boston #biotech hub. We also want to extend a warm welcome to our two new US colleagues, Moetaz Albizem, Senior VP and Head of Clinical Operations, and Yariv Houvras, MD PhD, VP Clinical and Translational Development. With their combined expertise in clinical drug development and medical affairs, particularly for antibody therapeutics, they will greatly contribute to advance the global clinical evaluation of our lead #ADC candidate, TUB-040, and support the transition of our preclinical candidates towards clinical phase. Learn more about our expert team and our pipeline of uniquely matched ADCs targeting #SolidTumors at www.tubulis.com
-
#ICYMI: Last month, Clarivate for Life Sciences & Healthcare featured us as 1 of 7 “Companies to Watch” in the #ADC space, highlighting our proprietary suite of technologies to unlock novel protein-drug combinations tailored to specific #cancer indications. See the post below to access the full report and learn more about how we are pushing the boundaries of ADC therapeutics at www.tubulis.com. Thank you to the whole Clarivate team for selecting us as one of the leading ADC innovators!
Tubulis GmbH, which aims to bring the true therapeutic value of ADCs to patients, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. The company combines disease-specific insight with its novel proprietary technologies, including the Tub-tag® and P5 conjugation platforms, to deliver a diverse range of targeting molecules and innovative payloads in ADCs developed in-house as well as by partners. Why is Tubulis a company to watch? Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/ezuGNPBk #oncology #cancertreatment #drugdiscovery #pharma
-
Tubulis' innovative research has been selected for a talk at the upcoming Medicinal Chemistry Gordon Research Conferences in New London, USA, which will be held by our VP Chemistry & Early Development, Marc-André Kasper, on August 13. In his presentation, he will speak about the trailblazing new #ADC linker technologies our team has developed to enable both the stable conjugation of previously “hard-to-link” alcohol-containing payloads, and their efficient on-target release at the #tumor site. These technologies are essential for the creation of our uniquely matched, disease-tailored ADC candidates with superior biophysical properties. Based on the latter, our goal is to reduce off-target effects and increase the therapeutic window. Find the agenda details here https://bit.ly/3Lwk4aq and learn more about our proprietary suite of ADC technologies at www.tubulis.com.
-
Tubulis GmbH hat dies direkt geteilt
Exciting News! Tubulis is one of Fierce Biotech’s 2024 #Fierce15 #biotech companies! Being selected for this prestigious industry award is an important recognition of our leadership position in the #ADC space and for the potential of our unique approach aiming to push the boundaries of ADCs. It is also a testament to all the hard work our team is putting in to drive innovation and realize our mission of improving the outcomes for cancer patients. We therefore want to thank every team member and our Board for their contributions! With our upsized Series B2 #financing in March, the start of our first clinical trial in June and the granting of #FDA Fast Track status for our lead candidate briefly afterwards, 2024 is a pivotal year for us. We are highly motivated to further building on this momentum and would like to thank the Fierce Biotech team for selecting us as one of this year’s fiercest companies! Click here to read the full announcement: https://bit.ly/4dmg2gY
-
Exciting News! Tubulis is one of Fierce Biotech’s 2024 #Fierce15 #biotech companies! Being selected for this prestigious industry award is an important recognition of our leadership position in the #ADC space and for the potential of our unique approach aiming to push the boundaries of ADCs. It is also a testament to all the hard work our team is putting in to drive innovation and realize our mission of improving the outcomes for cancer patients. We therefore want to thank every team member and our Board for their contributions! With our upsized Series B2 #financing in March, the start of our first clinical trial in June and the granting of #FDA Fast Track status for our lead candidate briefly afterwards, 2024 is a pivotal year for us. We are highly motivated to further building on this momentum and would like to thank the Fierce Biotech team for selecting us as one of this year’s fiercest companies! Click here to read the full announcement: https://bit.ly/4dmg2gY
-
The latest Flot.bio episode is out now! Listen in to hear Dominik Schumacher, our CEO, and Philip Hemme discuss Tubulis’ journey and the advancements we're making in the ADC biotech space. A big thank you to the Flot.bio team for featuring Dominik and Tubulis!
New episode from Munich 🇩🇪: here’s my conversation with Dominik Schumacher of Tubulis GmbH, best founders under 40 🚀 Gain insights from a “true” biotech founder, one of the only founder-PhDs under 40 that have scaled to raise over 100M. “There’s a lot of ADC development happening [in China] and the quality is really good. It’s competition that we look at seriously and take seriously.” We talked about building a champion ADC biotech, took a deep dive into the ADC sphere, and the difference between luck and success. You can now watch and listen to the full episode for free on YouTube, Spotify or Apple (link in the comments). What do you think? 🤔